Abstract 1035P
Background
IMC-002 is a fully human IgG4 antibody targeting CD47. IMC-002 induces phagocytosis of tumor cells by macrophages and significantly suppresses tumor growth in preclinical models of hematologic and solid tumors. Here we present preliminary safety, pharmacokinetics (PK), and efficacy data from ongoing phase 1 study of IMC-002 in patients with advanced solid tumors who failed to standard therapy (without priming dose).
Methods
We used a traditional 3+3 design to evaluate dose limiting toxicity (DLT) over 21 days, with 4 doses of IMC-002 (5, 10, 20 and 30 mg/kg). IMC-002 was administered intravenously once every 2 weeks until disease progression or unacceptable toxicity. Tumor assessments were performed every 6 weeks according to RECIST 1.1 criteria.
Results
As of May 2023, we enrolled 12 refractory patients (9 hepatocellular carcinoma, 2 breast cancer, 1 gallbladder cancer) with median age of 55 (range 39-73). Eleven of these patients were at stage IV with multiple distant metastases and high tumor burden. The median number of prior systemic therapy was 3 (range 1-3) and 4 patients received anti-PD-(L)1 antibody. The median interval between the last dose of previous therapy and IMC-002 was 1 month (range 1-4). No DLTs were observed across 4 dose levels. The majority of treatment related adverse events (TRAEs) were grade 1-2 (92%) and most of these events occurred during the first cycle (95%). TRAEs observed in more than 2 patients included transient vitreous floaters, skin rash, anemia and nausea. No infusion related reactions, thrombocytopenia, or neutropenia were reported. The serum exposure of IMC-002 (Cmax and AUC) increased with dose, and the predicted trough concentration exceeded the minimum efficacious concentration for IMC-002 when administered at a dose of over 10 mg/kg once every 2 weeks. Among the 11 efficacy evaluable patients, 5 had stable disease with a median treatment duration of 6 cycles (range 5-12). Among them, 4 had HCC and 1 had breast cancer.
Conclusions
IMC-002 demonstrated a favorable safety profile when administered intravenously every 2 weeks up to 30 mg/kg and showed preliminary efficacy in patients with advanced solid tumors. Based on safety and PK profile, we determined the recommended phase 2 dose as 20 mg/kg.
Clinical trial identification
NCT05276310.
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOncia Therapeutics, Inc.
Funding
ImmuneOncia Therapeutics, Inc.
Disclosure
H. Seon, J.K. Lee, S.Y. LEE, H.T. Kim: Financial Interests, Institutional, Full or part-time Employment: ImmuneOncia Therapeutics Inc.. All other authors have declared no conflicts of interest.
Resources from the same session
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19
1047P - AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Presenter: Ben Tran
Session: Poster session 19